Merck & Co looks to its traditional strengths in foray into follow-on biologics
This article was originally published in Scrip
Executive Summary
With sales growth for biologics expected to outpace that in the overall pharma sector over the next few years, it is not surprising that big pharma has been beefing up its presence in the sector through acquisitions and licensing deals.